We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Proteros Enters into a Research Agreement for Structure Based Lead Generation

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Enters into a Research Agreement for Structure Based Lead Generation"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Proteros biostructures GmbH (Proteros) announced that it has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), under which Proteros will perform research to discover small molecule lead compounds against a specific target for delivery to J&JPRD.

Under the agreement, Proteros will deploy its integrated Lead Discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and fragment library, compound profiling, and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.

Torsten Neuefeind, Chief Executive Officer for Proteros, stated that “this partnership will build on a long standing and successful relationship.”